JP2023517536A5 - - Google Patents

Info

Publication number
JP2023517536A5
JP2023517536A5 JP2022552946A JP2022552946A JP2023517536A5 JP 2023517536 A5 JP2023517536 A5 JP 2023517536A5 JP 2022552946 A JP2022552946 A JP 2022552946A JP 2022552946 A JP2022552946 A JP 2022552946A JP 2023517536 A5 JP2023517536 A5 JP 2023517536A5
Authority
JP
Japan
Prior art keywords
day
pharmaceutical composition
composition according
administered
stereoisomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022552946A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023517536A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/055187 external-priority patent/WO2021175857A1/en
Publication of JP2023517536A publication Critical patent/JP2023517536A/ja
Publication of JP2023517536A5 publication Critical patent/JP2023517536A5/ja
Pending legal-status Critical Current

Links

JP2022552946A 2020-03-02 2021-03-02 炎症状態に使用するための化合物 Pending JP2023517536A (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
EP20382152 2020-03-02
EP20382152.5 2020-03-02
EP20382192 2020-03-13
EP20382192.1 2020-03-13
EP20382266.3 2020-04-02
EP20382266 2020-04-02
EP20382339 2020-04-27
EP20382339.8 2020-04-27
EP20382816.5 2020-09-16
EP20382815 2020-09-16
EP20382815.7 2020-09-16
EP20382816 2020-09-16
EP21382059 2021-01-25
EP21382059.0 2021-01-25
PCT/EP2021/055187 WO2021175857A1 (en) 2020-03-02 2021-03-02 Compounds for use in inflammatory conditions

Publications (2)

Publication Number Publication Date
JP2023517536A JP2023517536A (ja) 2023-04-26
JP2023517536A5 true JP2023517536A5 (cg-RX-API-DMAC7.html) 2024-03-12

Family

ID=74732953

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022552946A Pending JP2023517536A (ja) 2020-03-02 2021-03-02 炎症状態に使用するための化合物
JP2022552937A Pending JP2023517535A (ja) 2020-03-02 2021-03-02 ウイルス感染に使用するための化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022552937A Pending JP2023517535A (ja) 2020-03-02 2021-03-02 ウイルス感染に使用するための化合物

Country Status (17)

Country Link
US (2) US12630589B2 (cg-RX-API-DMAC7.html)
EP (2) EP4114433A2 (cg-RX-API-DMAC7.html)
JP (2) JP2023517536A (cg-RX-API-DMAC7.html)
KR (2) KR20220151643A (cg-RX-API-DMAC7.html)
CN (2) CN115666616A (cg-RX-API-DMAC7.html)
AU (2) AU2021232535A1 (cg-RX-API-DMAC7.html)
BR (2) BR112022016604A2 (cg-RX-API-DMAC7.html)
CA (2) CA3169540A1 (cg-RX-API-DMAC7.html)
CL (2) CL2022002396A1 (cg-RX-API-DMAC7.html)
CO (2) CO2022014031A2 (cg-RX-API-DMAC7.html)
IL (2) IL296069A (cg-RX-API-DMAC7.html)
MX (2) MX2022010921A (cg-RX-API-DMAC7.html)
PE (2) PE20230412A1 (cg-RX-API-DMAC7.html)
PY (2) PY2117301A (cg-RX-API-DMAC7.html)
TW (2) TW202144381A (cg-RX-API-DMAC7.html)
UY (2) UY39110A (cg-RX-API-DMAC7.html)
WO (2) WO2021175831A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4114436A1 (en) * 2020-03-02 2023-01-11 Pharma Mar S.A. Compounds for use in the treatment of coronavirus infection
CN115666616A (zh) 2020-03-02 2023-01-31 法马马有限公司 用于病毒感染的化合物
IL296067A (en) * 2020-03-02 2022-11-01 Pharma Mar Sa Pld for use in combination in the treatment of coronavirus
WO2024165764A1 (en) * 2023-02-10 2024-08-15 Pharma Mar, S.A. Plitidepsin for use in the treatment of non-integrated dna viral infections
CN117285611B (zh) * 2023-11-24 2024-02-09 中国海洋大学 一种来源于海鞘的抗炎寡肽及其在制备药物中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4493796A (en) 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US20030148933A1 (en) * 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
BR9909668A (pt) * 1998-04-14 2000-12-19 Jomaa Hassan Uso de compostos de organofósforo para o tratamento terapêutico e profilático de infecções
ES2272462T3 (es) 2000-04-07 2007-05-01 The Trustees Of The University Of Pennsylvania Analogos de tamadarina y didemnina y procedimiento de fabricacion y uso.
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
JP4623931B2 (ja) * 2000-12-07 2011-02-02 エンセラデュス、ファーマシューティカルズ、ベスローテン、フェンノートシャップ 炎症性疾患の治療用組成物
US20070148192A1 (en) * 2003-02-21 2007-06-28 Laddha Ritu N Stable ophthalmic composition
AU2004224418A1 (en) 2003-03-21 2004-10-07 Madeleine M. Joullie Tamandarin analogs and fragments thereof and methods of making and using
HUE028055T2 (en) * 2006-02-28 2016-11-28 Pharma Mar Sa Improved treatment of myeloma multiplex
WO2011020913A2 (en) 2009-08-21 2011-02-24 Pharma Mar, S.A. Cyclodepsipeptide antiviral compounds
JP5814933B2 (ja) * 2009-12-15 2015-11-17 ノバルティス アーゲー 免疫増強化合物の均質な懸濁物およびその使用
US20120040033A1 (en) * 2010-08-10 2012-02-16 Ernest Timothy Armstrong Anti-infective mangrove extract against viruses, bacteria and fungi
GB201316524D0 (en) * 2013-09-17 2013-10-30 Medical Res Council Biomarkers
JP2017526728A (ja) * 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト
US11771739B2 (en) * 2017-06-16 2023-10-03 Vanderbilt University Methods and compositions for treating microbial inflammation
CN115666616A (zh) * 2020-03-02 2023-01-31 法马马有限公司 用于病毒感染的化合物

Similar Documents

Publication Publication Date Title
Mauss et al. A prospective controlled study of interferon‐based therapy of chronic hepatitis C in patients on methadone maintenance
JP2023517535A5 (cg-RX-API-DMAC7.html)
JP2011522862A (ja) テラプレビル(Telaprevir)投薬養生法
JP2013518124A5 (cg-RX-API-DMAC7.html)
JP2010530423A (ja) 免疫活性化剤を用いたウイルス感染の早期介入
US20060258738A1 (en) Use of dronabinol for treatment of side effects of Hepatitis C therapy
JP2024533153A5 (cg-RX-API-DMAC7.html)
CA2525202A1 (en) Use of alpha interferon, ribavirin, dsrna and neuraminidase inhibitors to treat avian influenza
JP2021004249A5 (cg-RX-API-DMAC7.html)
Kichloo et al. Emerging therapeutics in the management of COVID-19
Afaghi et al. Therapeutic options and critical care strategies in covid-19 patients; where do we stand in this battle?
CN102600129A (zh) 穿心莲内酯c15位取代衍生物在制备抗丙型肝炎药物中的应用
Gill et al. SGLT-2 inhibition: novel therapeutics for reno-and cardioprotection in diabetes mellitus
JP2023517295A5 (cg-RX-API-DMAC7.html)
Deterding et al. 1047 EARLY VERSUS DELAYED TREATMENT OF ACUTE HEPATITIS C: THE GERMAN HEP-NET ACUTE HCV-III STUDY–A RANDOMIZED CONTROLLED TRIAL
US20240350659A1 (en) Compositions and methods for bimodal anti-viral combination therapy
PH12014000275A1 (en) Antiviral pharmaceutical formulation for the effective treatment of dengue, influenza and hiv/aids
JP2023535710A (ja) SARS-CoV-2感染患者におけるアウトカムを改善するための吸入インターフェロン-ベータ
KUMARª et al. COVID-19 Pharmacotherapy–
WO2021236935A1 (en) Compositions and methods for treating lung injuries associated with viral infections
CN106562970A (zh) Gs‑9620的用途
Reiberger¹ et al. Efficacy and safety of glecaprevir/pibrentasvir in acute HCV participants with a history of prior infection (s)
Alavian Optimal therapy for hepatitis C
Hemmati et al. Off-label Use of Medicines in COVID-19: A Lesson For Future
Ortolá et al. 5PSQ-032 Effectiveness and safety in the use of sofosbubir/velpatasvir in the treatment of chronic hepatitis c virus infection